肺癌基因组检测市场－全球产业规模、份额、趋势、机会和预测，按组件、技术、检测板类型、样本类型、最终用户、地区和竞争格局划分，2021-2031年预测

全球肺癌基因组检测市场规模将从2025年的21.7亿美元成长到2031年的37.6亿美元，复合年增长率达9.59%。肺癌基因组检测涉及对肿瘤组织或液体活检样本进行分子分析，以识别特定的基因改变，例如EGFR突变或ALK重排，这些变化决定了标靶治疗方案的选择。推动市场成长的主要因素是临床向个人化医疗的转型以及伴随诊断对新型肿瘤药物上市许可的严格监管要求。

主要市场驱动因素

全球肺癌发生率和盛行率的不断上升是基因组检测市场发展的根本驱动力，不断扩大的患者群体对精准分子诊断的需求日益增长。由于全球肺癌负担依然沉重，医疗系统正日益要求所有新确诊患者进行全面的生物标记检测，以确定最有效的治疗策略。

主要市场挑战

下一代定序的报销政策不统一，是限制全球肺癌基因组检测市场成长的一大障碍。儘管临床指引日益建议进行全面的基因组分析，但缺乏统一的支付方覆盖范围造成了严重的经济摩擦，导致临床应用与病患可及性脱节。

主要市场趋势

从单基因检测到全面的下一代定序 (NGS) 检测，正在重塑肺癌的诊断标准。这项转变的驱动力在于，需要从有限的组织样本中有效地辨识多种可操作的基因改变。临床医生正逐渐放弃反覆的单生物标记检测（这种检测方式容易导致组织样本耗竭），转而采用广泛的基因组分析，以便在单一流程中捕获共存突变和復杂的特征，例如肿瘤突变负荷。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球肺癌基因组检测市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按组成部分（产品与服务）
  • 依技术分类（次世代定序、聚合酶炼式反应、萤光原位杂交（FISH）/原位杂交（ISH）、其他）
  • 依检测类型（单基因检测与多基因检测）
  • 依样本类型（组织活检与液体活检）
  • 按最终用户分类（学术和研究机构、医院和诊所、诊断实验室、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美肺癌基因组检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肺癌基因组检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区肺癌基因组检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲肺癌基因组检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲肺癌基因组检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球肺癌基因组检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE NV
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

第十六章：策略建议

第17章调查会社について・免责事项

The Global Lung Cancer Genomic Testing Market will grow from USD 2.17 Billion in 2025 to USD 3.76 Billion by 2031 at a 9.59% CAGR. Lung cancer genomic testing involves the molecular analysis of tumor tissue or liquid biopsies to identify specific genetic alterations such as EGFR mutations or ALK rearrangements that dictate the selection of targeted therapies. The market is primarily propelled by the clinical transition toward personalized medicine and the stringent regulatory requirement for companion diagnostics to authorize the use of novel oncology drugs.

Key Market Drivers

The Rising Global Incidence and Prevalence of Lung Cancer serves as the foundational catalyst for the genomic testing market, creating an expanding patient pool that necessitates precise molecular diagnosis. As the burden of lung malignancy remains high globally, healthcare systems are increasingly mandating comprehensive biomarker testing for all newly diagnosed patients to determine the most effective management strategies. This volume-driven demand is evidenced by the sheer scale of diagnoses in major markets.

Key Market Challenges

The inconsistent reimbursement landscape for next-generation sequencing constitutes a substantial barrier hampering the growth of the Global Lung Cancer Genomic Testing Market. While clinical guidelines increasingly recommend comprehensive profiling, the lack of uniform payer coverage creates severe economic friction that disconnects clinical availability from patient accessibility. Diagnostic developers face restricted revenue potential as healthcare providers often hesitate to order advanced genomic profiling due to uncertainty regarding payment authorization.

Key Market Trends

The transition from single-gene assays to comprehensive next-generation sequencing (NGS) panels is reshaping the diagnostic standard for lung malignancy, driven by the need to efficiently identify multiple actionable alterations from limited tissue samples. Clinicians are increasingly abandoning iterative single-biomarker testing, which risks tissue exhaustion, in favor of broad genomic profiling that captures co-occurring mutations and complex signatures like tumor mutational burden in a single workflow. This consolidation is critical for matching patients to the growing array of targeted therapies without the latency of sequential testing.

Key Market Players

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE N.V.
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Market, By Component:

• Products v/s Services

Lung Cancer Genomic Testing Market, By Technology:

• Next Generation Sequencing
• Polymerase Chain Reactions
• Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)
• Others

Lung Cancer Genomic Testing Market, By Panel Type:

• Single Panel v/s Multi-Gene Panel

Lung Cancer Genomic Testing Market, By Sample Type:

• Tissue Biopsy v/s Liquid Biopsy

Lung Cancer Genomic Testing Market, By End User:

• Academic & Research Institutions
• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Lung Cancer Genomic Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Genomic Testing Market.

Available Customizations:

Global Lung Cancer Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Genomic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Products v/s Services)
  • 5.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others)
  • 5.2.3. By Panel Type (Single Panel v/s Multi-Gene Panel)
  • 5.2.4. By Sample Type (Tissue Biopsy v/s Liquid Biopsy)
  • 5.2.5. By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Lung Cancer Genomic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Technology
  • 6.2.3. By Panel Type
  • 6.2.4. By Sample Type
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Genomic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Panel Type
      • 6.3.1.2.4. By Sample Type
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Lung Cancer Genomic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Panel Type
      • 6.3.2.2.4. By Sample Type
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Lung Cancer Genomic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Panel Type
      • 6.3.3.2.4. By Sample Type
      • 6.3.3.2.5. By End User

7. Europe Lung Cancer Genomic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Technology
  • 7.2.3. By Panel Type
  • 7.2.4. By Sample Type
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lung Cancer Genomic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Panel Type
      • 7.3.1.2.4. By Sample Type
      • 7.3.1.2.5. By End User
  • 7.3.2. France Lung Cancer Genomic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Panel Type
      • 7.3.2.2.4. By Sample Type
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Lung Cancer Genomic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Panel Type
      • 7.3.3.2.4. By Sample Type
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Lung Cancer Genomic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Panel Type
      • 7.3.4.2.4. By Sample Type
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Lung Cancer Genomic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Panel Type
      • 7.3.5.2.4. By Sample Type
      • 7.3.5.2.5. By End User

8. Asia Pacific Lung Cancer Genomic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Technology
  • 8.2.3. By Panel Type
  • 8.2.4. By Sample Type
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Genomic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Panel Type
      • 8.3.1.2.4. By Sample Type
      • 8.3.1.2.5. By End User
  • 8.3.2. India Lung Cancer Genomic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Panel Type
      • 8.3.2.2.4. By Sample Type
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Lung Cancer Genomic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Panel Type
      • 8.3.3.2.4. By Sample Type
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Lung Cancer Genomic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Panel Type
      • 8.3.4.2.4. By Sample Type
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Lung Cancer Genomic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Panel Type
      • 8.3.5.2.4. By Sample Type
      • 8.3.5.2.5. By End User

9. Middle East & Africa Lung Cancer Genomic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Technology
  • 9.2.3. By Panel Type
  • 9.2.4. By Sample Type
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lung Cancer Genomic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Panel Type
      • 9.3.1.2.4. By Sample Type
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Lung Cancer Genomic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Panel Type
      • 9.3.2.2.4. By Sample Type
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Lung Cancer Genomic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Panel Type
      • 9.3.3.2.4. By Sample Type
      • 9.3.3.2.5. By End User

10. South America Lung Cancer Genomic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Technology
  • 10.2.3. By Panel Type
  • 10.2.4. By Sample Type
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lung Cancer Genomic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Panel Type
      • 10.3.1.2.4. By Sample Type
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Lung Cancer Genomic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Panel Type
      • 10.3.2.2.4. By Sample Type
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Lung Cancer Genomic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Panel Type
      • 10.3.3.2.4. By Sample Type
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lung Cancer Genomic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. QIAGEN NV
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Quest Diagnostics Incorporated
• 15.5. Laboratory Corporation of America Holdings
• 15.6. CENTOGENE N.V.
• 15.7. BGI Genomics Co. Ltd.
• 15.8. CeGaT GmbH
• 15.9. Illumina Inc.
• 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer